139 related articles for article (PubMed ID: 15250065)
21. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
Black DM; Bilezikian JP; Ensrud KE; Greenspan SL; Palermo L; Hue T; Lang TF; McGowan JA; Rosen CJ;
N Engl J Med; 2005 Aug; 353(6):555-65. PubMed ID: 16093464
[TBL] [Abstract][Full Text] [Related]
22. Alendronate.
Hamdy RC
South Med J; 1999 Nov; 92(11):1118-20. PubMed ID: 10586845
[No Abstract] [Full Text] [Related]
23. Daily and cyclic parathyroid hormone in women receiving alendronate.
Cosman F; Nieves J; Zion M; Woelfert L; Luckey M; Lindsay R
N Engl J Med; 2005 Aug; 353(6):566-75. PubMed ID: 16093465
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
Ralston SH; Binkley N; Boonen S; Kiel DP; Reginster JY; Roux C; Chen L; Rosenberg E; Santora A;
Calcif Tissue Int; 2011 Jun; 88(6):485-94. PubMed ID: 21479913
[TBL] [Abstract][Full Text] [Related]
25. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
[TBL] [Abstract][Full Text] [Related]
26. Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis.
Dempster DW
J Bone Miner Res; 1997 Aug; 12(8):1152-4. PubMed ID: 9258744
[No Abstract] [Full Text] [Related]
27. The effects of alendronate in postmenopausal women with osteoporosis.
Yaniv I
Osteoporos Int; 2003 Jan; 14(1):90-1. PubMed ID: 12577190
[No Abstract] [Full Text] [Related]
28. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing.
Colón-Emeric CS
JAMA; 2006 Dec; 296(24):2968-9. PubMed ID: 17190899
[No Abstract] [Full Text] [Related]
29. Postmenopausal osteoporosis and alendronate.
Pérez-López FR
Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
[TBL] [Abstract][Full Text] [Related]
30. [Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D].
Grazio S; Morović-Vergles J
Reumatizam; 2007; 54(2):89-92. PubMed ID: 18351154
[TBL] [Abstract][Full Text] [Related]
31. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.
Creatsa M; Pliatsika P; Kaparos G; Antoniou A; Armeni E; Tsakonas E; Panoulis C; Alexandrou A; Dimitraki E; Christodoulakos G; Lambrinoudaki I
J Obstet Gynaecol Res; 2011 Oct; 37(10):1415-22. PubMed ID: 21651652
[TBL] [Abstract][Full Text] [Related]
32. [Current osteoporosis treatment: reasons for adding vitamin D to alendronate].
Anić B; Grazio S
Reumatizam; 2006; 53(2):63-5. PubMed ID: 17580557
[TBL] [Abstract][Full Text] [Related]
33. Alendronate treatment for osteoporosis.
Brager R
Adv Nurse Pract; 1997 Mar; 5(3):28-34. PubMed ID: 9459879
[No Abstract] [Full Text] [Related]
34. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
35. Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
Sebastián-Ochoa A; Fernández-García D; Reyes-García R; Mezquita-Raya P; Rozas-Moreno P; Alonso-Garcia G; Muñoz-Torres M
Menopause; 2012 Feb; 19(2):172-7. PubMed ID: 21971209
[TBL] [Abstract][Full Text] [Related]
36. Decimal point--osteoporosis therapy at the 10-year mark.
Strewler GJ
N Engl J Med; 2004 Mar; 350(12):1172-4. PubMed ID: 15028820
[No Abstract] [Full Text] [Related]
37. [Working title: Will reducing alendronate increase the risk of bone fractures by a decrease in bone density? Benefit from alendronate therapy for women without prior fractures remains uncertain].
Ritzmann P
Praxis (Bern 1994); 1999 Sep; 88(40):1631-2. PubMed ID: 10536501
[No Abstract] [Full Text] [Related]
38. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis].
Cheng ZQ; Yin W; Fan JY; Ma TJ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun; 24(3):306-9. PubMed ID: 12905641
[TBL] [Abstract][Full Text] [Related]
39. [To increase bone density faster and stronger].
MMW Fortschr Med; 2005 May; 147(18):44-5. PubMed ID: 15934589
[No Abstract] [Full Text] [Related]
40. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
